Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Scholar Rock Holding Stock

Price
Target price
€8.65

€8.65

2.310%
0.2
2.310%
€21.78
 
31.05.24 / Tradegate WKN: A2JMQW / Symbol: SRRK / Name: Scholar Rock / Stock / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Scholar Rock Holding in the next few years
Wizard

Scholar Rock Holding Stock

There is an upward development for Scholar Rock Holding compared to yesterday, with an increase of €0.20 (2.310%).
With 14 Buy predictions and not the single Sell prediction the community is currently very high on Scholar Rock Holding.
With a target price of 21 € there is potential for a 142.77% increase which would mean more than doubling the current price of 8.65 € for Scholar Rock Holding.

Scholar Rock is a clinical-stage biopharmaceutical company that engages in the discovery and development of innovative medicines to treat serious diseases in patients that currently have limited or no treatment options. Their pipeline consists of a number of product candidates that target growth factor signaling pathways within the human body. These products hold potential for the treatment of multiple diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock, which trades under the symbol SRRK, is listed on the NASDAQ stock exchange.

Pros and Cons of Scholar Rock Holding in the next few years

Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Comments

Prediction Buy
Perf. (%) -16.83%
Target price 27.633
Change
Ends at 23.05.25

Scholar Rock Holding Co. (NASDAQ: SRRK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Ratings data for SRRK provided by MarketBeat
Show more

HC Wainwright 
0
Report Share
23.05.24
Prediction Buy
Perf. (%) -35.93%
Target price 27.891
Change
Ends at 08.05.25

Scholar Rock Holding Co. (NASDAQ: SRRK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Ratings data for SRRK provided by MarketBeat
Show more

HC Wainwright 
0
Report Share
08.05.24
Prediction Buy
Perf. (%) -35.93%
Target price 21.381
Change
Ends at 07.05.25

Scholar Rock Holding Co. (NASDAQ: SRRK) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $23.00 price target on the stock.
Ratings data for SRRK provided by MarketBeat
Show more

Wedbush 
0
Report Share
07.05.24
Show more
Not a member yet? Sign up for free!

News

Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity: https://mms.businesswire.com/media/20211102005274/en/922183/5/Logo_2020.jpg
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity


Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious

BusinessWire_EN 
0 22.05.24
Scholar Rock to Participate in Upcoming Investor Conferences: https://mms.businesswire.com/media/20211102005274/en/922183/5/Logo_2020.jpg
Scholar Rock to Participate in Upcoming Investor Conferences


Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious

BusinessWire_EN 
0 20.05.24
Scholar Rock to Host Investor Day on May 22, 2024: https://mms.businesswire.com/media/20211102005274/en/922183/5/Logo_2020.jpg
Scholar Rock to Host Investor Day on May 22, 2024


Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious

BusinessWire_EN 
0 14.05.24